BeyondSpring has been granted a patent for a pharmaceutical composition containing a compound of Formula (I) for treating cancer. The composition can be co-administered with immune checkpoint inhibitors or plinabulin to enhance T-cell activation against cancer. GlobalData’s report on BeyondSpring gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BeyondSpring, Cancer treatment biomarkers was a key innovation area identified from patents. BeyondSpring's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating cancer
A recently granted patent (Publication Number: US11857522B2) discloses a pharmaceutical composition comprising a compound of Formula (I) along with a first immune checkpoint inhibitor and a second immune checkpoint inhibitor. The first and second immune checkpoint inhibitors can independently target PD-1, PD-L1, PD-L2, or CTLA-4, with specific combinations like a PD-1 inhibitor paired with a CTLA-4 inhibitor. The immune checkpoint inhibitors in the composition are antibodies, including a variety of specific antibodies targeting different immune markers.
Furthermore, the patent also covers methods for treating cancer by co-administering the compound of Formula (I) with additional chemotherapeutic agents. The cancer types that can be targeted include head and neck cancer, lung cancer, stomach cancer, colon cancer, and various others. The immune checkpoint inhibitors used in the treatment methods include well-known options like nivolumab, pembrolizumab, and ipilimumab, either alone or in combination. The compound of Formula (I) mentioned in the patent, tucaresol, is highlighted as a key component in the treatment methods for various cancer types, showcasing its potential in cancer therapy.
To know more about GlobalData’s detailed insights on BeyondSpring, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
